Founded in Philadelphia, Longevity Biotech focuses on developing Hybridtides, a new class of therapeutic candidates aimed at addressing some of the most challenging aspects of modern medicine. The company’s core mission is to deliver clinically transformative products, leveraging their breakthrough peptide technology to create unique drug profiles. Their market focus includes preclinical development programs and optimizing oral peptide delivery through proprietary databases.
Notable affiliated individuals and investors include experts in biotechnology and pharmaceuticals, though specific names are not provided. Key achievements include the development of multiple preclinical programs based on their Hybridtide technology. Longevity Biotech's impact lies in its innovative approach to drug development, potentially transforming treatment paradigms for various medical conditions.
